On October 17, PhRMA (the Pharmaceutical Research and Manufacturers of America) submitted its recommendations to the Office of the United States Trade Representative (USTR) for the 2025 National Trade Estimate (NTE) Report on Foreign Trade Barriers. PhRMA's submission highlights significant intellectual property (IP) and market access challenges in over two dozen countries that jeopardize American jobs and the export of innovative medicines. It also emphasizes that current U.S. trade policies have been insufficient in addressing these issues, underscoring the need for the next U.S. Administration to take a stronger stance in defending American innovation internationally.
As a global leader in biopharmaceutical research and development, the U.S. biopharmaceutical sector supports over 4.9 million American jobs and ranks as the top exporter among R&D-intensive industries in the country. This critical industry depends on fair international market access and strong IP protections to compete effectively and deliver life-saving treatments worldwide.
However, many foreign governments continue to impose restrictive measures on U.S. innovators. Examples include:
- Price controls in countries like Canada and Japan, which act as non-tariff trade barriers and prevent fair competition for American companies.
- Korea’s lack of transparent policies valuing American-made medicines, despite obligations under the U.S.-Korea Free Trade Agreement.
- Mexico’s delay in implementing key IP protections under the United States-Mexico-Canada Agreement (USMCA).
- The European Union's proposals that link IP incentives to product launches across all EU member states, which would discourage R&D and limit patient access to new treatments.
Key Concerns Raised by PhRMA
Intellectual Property Protection: PhRMA emphasized that weak IP protections in certain countries can undermine U.S. innovation and investments in drug development. Intellectual property rights are crucial for biopharmaceutical companies, as they enable firms to recoup significant research and development costs. PhRMA highlighted specific countries where inadequate IP protections are negatively affecting U.S. pharmaceutical companies, making it harder to bring new medicines to global markets.
Market Access Barriers: PhRMA pointed out that some countries maintain policies that restrict access to the market for U.S.-based pharmaceuticals, such as unfair pricing and reimbursement practices. These policies can create barriers that prevent American companies from competing on a level playing field, ultimately limiting access to innovative therapies in these regions.
Data Exclusivity: Another significant concern for PhRMA is the protection of clinical data submitted for regulatory approval. Some countries lack adequate protections, allowing generic versions of drugs to enter the market prematurely and impacting the profits and incentives for continued innovation.
Enforcement of Trade Agreements: PhRMA called for better enforcement of trade agreements, especially those with IP protections. The organization argues that while the U.S. has entered agreements aimed at improving IP standards, lax enforcement in other countries means these standards are often not met, compromising the integrity of international trade agreements.
PhRMA’s Recommendations for USTR
To address these concerns, PhRMA recommended several adjustments to the USTR's approach:
Strengthening IP Protections in Trade Agreements: PhRMA encouraged USTR to pursue new trade agreements or renegotiate existing ones to strengthen IP protections globally. For instance, they suggest including provisions that would enforce longer periods of data exclusivity and require stricter standards for patent protection, especially in countries known for weak IP laws.
Improved Market Access: PhRMA advocates for the USTR to prioritize reducing foreign trade barriers that limit U.S. biopharmaceutical companies’ market access. This could include negotiating fairer pricing policies and reimbursement systems, particularly in markets with significant purchasing power.
Targeted Enforcement Actions: PhRMA urged the USTR to implement more aggressive enforcement of trade rules when countries fail to meet their IP protection commitments. This could mean imposing tariffs, pursuing dispute resolutions, or taking legal action in international courts to encourage compliance.
Transparency and Accountability: PhRMA called for greater transparency in how trade policies are enforced and recommended regular assessments to ensure compliance. PhRMA also suggested that countries failing to meet their trade commitments face accountability measures, ensuring that IP protections are taken seriously.
Impact of Proposed Changes
PhRMA believes that by strengthening trade policies and IP enforcement, the U.S. can enhance its global competitiveness and incentivize continued innovation in the pharmaceutical industry. Protecting IP more robustly will allow U.S. biopharmaceutical companies to maintain a lead in the development of life-saving drugs, which benefits both the U.S. economy and global public health. Additionally, stronger IP laws and enforcement could encourage other countries to develop more consistent policies, reducing risks for American businesses and promoting a more balanced international trade environment.
These policies erode U.S. global competitiveness and reduce patient access to innovative medicines. PhRMA argues that the Biden Administration has not fully enforced IP commitments made by U.S. trading partners and has declined to pursue new trade agreements that would strengthen IP protections and market access for American companies abroad.
To preserve U.S. jobs and leadership in the biopharmaceutical industry, the next Administration must adopt a more assertive trade approach, prioritizing trade agreements and enforcement actions that defend American IP and ensure fair international market access.
Conclusion
PhRMA’s submission to the USTR underscores the importance of robust IP protection, fair market access, and strict enforcement of trade policies to foster innovation in the U.S. pharmaceutical sector. By calling on the USTR to adjust its trade policy and enforcement measures, PhRMA aims to create a fairer and more supportive environment for American biopharmaceutical companies to thrive globally.

0 Comments